Kinase inhibition is a major area for therapeutic intervention against a variety of diseases including cancer, inflammatory disorders and diabetes. While this mode of action remains very promising at this time, it faces critical challenges, such as drug safety, and biopharmaceutical profile. This review provides an update on kinase inhibitor pharmacophores from a structural standpoint. Advances in older inhibitor classes as well as new emerging lead structures will be presented.
No takes yet. Share an insight, caveat, or question.
Jacques Dumas (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: